The purpose of the assessment is to evaluate Ramucirumab (Cyramza®) in combination with Paclitaxel for the treatment of gastric cancer.
Final version of the assessment was published in March 2015
Below is the documentation provided by the Joint Assessment authoring team:
WP5-SA-4_RAMUCIRUMAB for the treatment of gastric cancer_APPENDIX_6_INCLUDED
Ramucirumab for the treatment of gastric cancer_Rapid REA_Final_Mar2015